Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

Exclusion Criteria

• •1. Contraindication for the administration of esmolol (according to technical data sheet): Hypersensitivity to esmolol hydrochloride; Severe sinus bradycardia (HR \<50 bpm); 2nd or 3rd degree atrioventricular block without pacemaker; Cardiogenic shock, severe hypotension, or decompensated heart failure; Untreated pheochromocytoma; Acute asthmatic attack; Concomitant intravenous administration or within the first 48 hours after verapamil.
• •2. Treatment with beta-blocker drugs (oral, topical or intravenous) in the last 7 days before the study.
• •3. History of ventricular or supraventricular arrhythmias that prevent the safe withdrawal of antiarrhythmic or braking treatment before the administration of esmolol.
• •4. History of previous high-grade atrioventricular (AV) conduction disorder in non-pacemaker patients.
• •5. Severe asthma with bronchial hyperresponsiveness.
• •6. Patients with acute infection.
• •7. Participants in other clinical trials in the 30 days prior to the start of the study.
• •8. Pregnant women, or who plan to be, and women during breastfeeding.
• •9. Patients with limitation to follow the protocol for any reason.
• •10. Diagnosis of Diabetes Mellitus (DM) of any type other than type 2 \[type 1, Latent Autoimmune Diabetes in Adults (LADA), Maturity-Onset Diabetes of the Young (MODY), New Onset Diabetes After Transplant (NODAT), etc.\]
• •11. Patients in New York Heart Association (NYHA) functional class IV or with advanced heart failure.
• •12. Treatment with an oral beta-blocker at the time of the examination that cannot be safely temporarily suspended 72 hours before the test.
• •13. Active evidence of Hepatitis B Virus (HBV) or Hepatitis B Virus (HCV) infection.
• •14. Personal history of previous cancer requiring systemic treatment (excludes skin or localized cancers treated locally surgically).
• •15. Previous exposure to systemic antitumor treatment or radiotherapy on the thoracic region.